The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
Open accessAbstract
Inhibitors selective for prostaglandin G/H synthase-2 (PGHS-2) (known colloquially as COX-2) were designed to minimize gastrointestinal complications of traditional NSAIDs--adverse effects attributed to suppression of COX-1-derived PGE2 and prostacyclin (PGI2). Evidence from 2 randomized controlled-outcome trials (RCTs) of 2 structurally distinct selective inhibitors of COX-2 supports this hypothesis. However, 5 RCTs of 3 structurally distinct inhibitors also indicate that such compounds elevate the risk of myocardial infarction and stroke. The clinical information is biologically plausible, as it is compatible with evidence that inhibition of COX-2-derived PGI2 removes a protective constraint on thrombogenesis, hypertension, and atherogenesis in vivo. However, the concept of simply tipping a "balance" between COX-2-derived PGI2 and COX-1-derived platelet thromboxane is misplaced. Among the questions that remain to be addressed are the following: (a) whether this hazard extends to all or some of the traditional NSAIDs; (b) whether adjuvant therapies, such as low-dose aspirin, will mitigate the hazard and if so, at what cost; (c) whether COX-2 inhibitors result in cardiovascular risk transformation during chronic dosing; and (d) how we might identify individuals most likely to benefit or suffer from such drugs in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., Gildehaus, D., iyashiro, J. M., Penning, T. D., Seibert, K., et al. (1996) · Nature · doi:10.1038/384644a0 · Cited by 1,917
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7563 · Cited by 1,519
Hla, T., & Neilson, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7384 · Cited by 1,465
Cited by
Chen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,742
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114147 · Cited by 1,920
Lansky, E. P., & Newman, R. A. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.09.006 · Cited by 1,290
Triggers, targets and treatments for thrombosis
Mackman, N. (2008) · Nature · doi:10.1038/nature06797 · Cited by 1,188
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
Trelle, S., Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P. M., Egger, M., & Juni, P. (2011) · BMJ · doi:10.1136/bmj.c7086 · Cited by 1,166
Harirforoosh, S., Asghar, W., & Jamali, F. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vw2f · Cited by 960
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
Patrono, C., Baigent, C., Hirsh, J., & Roth, G. (2008) · Chest · doi:10.1378/chest.08-0672 · Cited by 748
Activation of Platelet Function Through G Protein–Coupled Receptors
Offermanns, S. (2006) · Circulation Research · doi:10.1161/01.res.0000251742.71301.16 · Cited by 725
“A shape change is the initial response of platelets to activators such as thrombin, ADP, or TxA2.”
BackgroundInfluentialEndocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation
Nomura, D. K., Morrison, B. E., Blankman, J. L., Long, J. Z., Kinsey, S. G., Marcondes, M. C. G., Ward, A. M., Hahn, Y. K., Lichtman, A. H., Conti, B., et al. (2011) · Science · doi:10.1126/science.1209200 · Cited by 727
Cyclooxygenases: structural and functional insights
Rouzer, C. A., & Marnett, L. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800042-jlr200 · Cited by 688
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases
Imig, J. D., & Hammock, B. D. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2875 · Cited by 614
McGettigan, P., & Henry, D. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001098 · Cited by 571
Structural and Functional Basis of Cyclooxygenase Inhibition
Blobaum, A. L., & Marnett, L. J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0613166 · Cited by 550
Prostanoids in health and disease
Smyth, E. M., Grosser, T., Wang, M., Yu, Y., & FitzGerald, G. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800094-jlr200 · Cited by 543
Self-citationMembrane Prostaglandin E Synthase-1: A Novel Therapeutic Target
Samuelsson, B., Morgenstern, R., & Jakobsson, P.-J. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.3.1 · Cited by 538
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Cannon, C. P., Curtis, S. P., FitzGerald, G. A., Krum, H., Kaur, A., Bolognese, J. A., Reicin, A. S., Bombardier, C., Weinblatt, M. E., van der Heijde, D., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69666-9 · Cited by 522
Translating molecular discoveries into new therapies for atherosclerosis
Rader, D. J., & Daugherty, A. (2008) · Nature · doi:10.1038/nature06796 · Cited by 515
Enzymes of the Cyclooxygenase Pathways of Prostanoid Biosynthesis
Smith, W. L., Urade, Y., & Jakobsson, P.-J. (2011) · Chemical Reviews · doi:10.1021/cr2002992 · Cited by 503
Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology
Altman, R., Bosch, B., Brune, K., Patrignani, P., & Young, C. (2015) · Drugs · doi:10.1007/s40265-015-0392-z · Cited by 493
Signalling networks regulating cyclooxygenase-2
Tsatsanis, C., Androulidaki, A., Venihaki, M., & Margioris, A. N. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.03.021 · Cited by 492
New insights into the use of currently available non-steroidal anti-inflammatory drugs
Brune, & Patrignani, P. (2015) · Journal of Pain Research · doi:10.2147/jpr.s75160 · Cited by 469
McGettigan, P., & Henry, D. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001388 · Cited by 414
Cardiovascular effects and safety of (non-aspirin) NSAIDs
Schjerning, A.-M., McGettigan, P., & Gislason, G. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0366-z · Cited by 387
Eikelboom, J. W., Hirsh, J., Spencer, F. A., Baglin, T. P., & Weitz, J. I. (2012) · Chest · doi:10.1378/chest.11-2293 · Cited by 379
Inflammation in atherosclerosis
Taleb, S. (2016) · Archives of Cardiovascular Diseases · doi:10.1016/j.acvd.2016.04.002 · Cited by 375
Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.764530 · Cited by 367
A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals
Wei, B. Q., Mikkelsen, T. S., McKinney, M. K., Lander, E. S., & Cravatt, B. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606646200 · Cited by 363
Theken, K. N., Lee, C. R., Gong, L., Caudle, K. E., Formea, C. M., Gaedigk, A., Klein, T. E., Agúndez, J. A. G., & Grosser, T. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1830 · Cited by 351
Self-citationDrugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics
Li, P., Zheng, Y., & Chen, X. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00460 · Cited by 346
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function
Cheng, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27540 · Cited by 339
Old and new generation lipid mediators in acute inflammation and resolution
Stables, M. J., & Gilroy, D. W. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.07.005 · Cited by 334
COX-2 Inhibitors and Cardiovascular Risk
Funk, C. D., & FitzGerald, G. A. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318157f72d · Cited by 330
Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases
Pettipher, R., Hansel, T. T., & Armer, R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2266 · Cited by 317
Prostaglandins in bone: bad cop, good cop?
Blackwell, K. A., Raisz, L. G., & Pilbeam, C. C. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.12.004 · Cited by 311
García Rodríguez, L. A., Tacconelli, S., & Patrignani, P. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.041 · Cited by 305
Patient blood management in Europe
Shander, A., Van Aken, H., Colomina, M. J., Gombotz, H., Hofmann, A., Krauspe, R., Lasocki, S., Richards, T., Slappendel, R., & Spahn, D. R. (2012) · British Journal of Anaesthesia · doi:10.1093/bja/aes139 · Cited by 300
Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation
Kang, Y.-J., Mbonye, U. R., DeLong, C. J., Wada, M., & Smith, W. L. (2007) · Progress in Lipid Research · doi:10.1016/j.plipres.2007.01.001 · Cited by 299
Roles of reactive oxygen and nitrogen species in pain
Salvemini, D., Little, J. W., Doyle, T., & Neumann, W. L. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.01.026 · Cited by 295
Gislason, G. H., Rasmussen, J. N., Abildstrom, S. Z., Schramm, T. K., Hansen, M. L., Fosbøl, E. L., Sørensen, R., Folke, F., Buch, P., Gadsbøll, N., et al. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.525 · Cited by 295
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer
Howe, L. R. (2007) · Breast Cancer Research · doi:10.1186/bcr1678 · Cited by 293
Solomon, S. D., Pfeffer, M. A., McMurray, J. J. V., Fowler, R., Finn, P., Levin, B., Eagle, C., Hawk, E., Lechuga, M., Zauber, A. G., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.636746 · Cited by 273
Carvacrol, a component of thyme oil, activates PPARα and γ and suppresses COX-2 expression
Hotta, M., Nakata, R., Katsukawa, M., Hori, K., Takahashi, S., & Inoue, H. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m900255-jlr200 · Cited by 260
The Anti-Inflammatory Effects of Prostaglandins
Scher, J. U., & Pillinger, M. H. (2009) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31819aaa76 · Cited by 259
Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions
Undas, A., Brummel-Ziedins, K. E., & Mann, K. G. (2007) · Blood · doi:10.1182/blood-2006-01-010645 · Cited by 254
Hypertension: Physiology and Pathophysiology
Hall, J. E., Granger, J. P., do Carmo, J. M., da Silva, A. A., Dubinion, J., George, E., Hamza, S., Speed, J., & Hall, M. E. (2012) · Comprehensive Physiology · doi:10.1002/cphy.c110058 · Cited by 232
Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346)
Wallace, J. L., Caliendo, G., Santagada, V., & Cirino, G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00611.x · Cited by 231
Warner, T. D., & Mitchell, J. A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60137-3 · Cited by 166
Schmidt, M., Lamberts, M., Olsen, A.-M. S., Fosbøll, E., Niessner, A., Tamargo, J., Rosano, G., Agewall, S., Kaski, J. C., Kjeldsen, K., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv505 · Cited by 164
Citral, a component of lemongrass oil, activates PPARα and γ and suppresses COX-2 expression
Katsukawa, M., Nakata, R., Takizawa, Y., Hori, K., Takahashi, S., & Inoue, H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.07.004 · Cited by 120
Novel Aspects of Endothelium-Dependent Regulation of Vascular Tone
Villar, I. C., Francis, S., Webb, A., Hobbs, A. J., & Ahluwalia, A. (2006) · Kidney International · doi:10.1038/sj.ki.5001680 · Cited by 112
Chan, M. V., & Wallace, J. L. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00169.2013 · Cited by 98
Yin, H., Gao, L., Tai, H.-H., Murphey, L. J., Porter, N. A., & Morrow, J. D. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608975200 · Cited by 82
García Rodríguez, L. A., González-Pérez, A., Bueno, H., & Hwa, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016780 · Cited by 59
Aljofan, M., & Ding, H. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.21986 · Cited by 58
Castillero, E., Martín, A. I., López-Menduiña, M., Villanúa, M. A., & López-Calderón, A. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00388.2009 · Cited by 53
Metadata
- Authors
- Grosser, T.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-12-08
- Volume
- 116
- Issue
- 1
- Pages
- 4-15
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2096874183
- Cited by
- 1,027
- References
- 111
- FWCI
- 46.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.